FIGURE 4.
Progression-free survival is shown (a) overall, for patients who received prior imatinib at doses of (b) 600 mg or (c) 400 mg, and for patients with (d) primary resistance and (e) acquired resistance. Patients without disease progression and those who remained alive at the time of last follow-up were censored at the last dosing date if they were off initial treatment or at the last assessment date if they were receiving initial treatment.